Cancer Stem Cells Market

Cancer Stem Cells Market

The global cancer stem cells market size reached USD 1.91 billion in 2024 and is estimated to hit around USD 5.8 billion by 2032 with a CAGR of 12.15% from 2024 to 2033. The rising prevalence of cancer cases all around the world and the rising investment in the development of cancer treatment are driving the growth of the cancer stem cells market.

Cancer Stem Cells Market: Key Trends

The rapid integration of stem cells in healthcare practices for tissue regeneration and as carriers of anti-cancer drugs is driving the expansion of the cancer stem cells market. Healthcare providers globally are witnessing favorable results from utilizing stem cells in tumor treatment. Nevertheless, the elevated expenses associated with stem cell therapy and the stringent regulations imposed by international healthcare authorities on its usage are impeding the progress of the cancer stem cells market.

Cancer Stem Cells Market

Size, by Product, - (USD Billion)

Breast

Bladder

Lung

Brain

Other Products

The Market will Grow

At the CAGR of:

12.15%

The Forecast Market

Size for in USD:

$5.8 Billion

Market Dynamics:

Driver

 Rising cases of cancer and increased funding in global cancer research & development programs

The rapid integration of stem cells in healthcare practices for tissue regeneration and as carriers of anti-cancer drugs is driving the expansion of the cancer stem cells market. Healthcare providers globally are witnessing favorable results from utilizing stem cells in tumor treatment. Nevertheless, the elevated expenses associated with stem cell therapy and the stringent regulations imposed by international healthcare authorities on its usage are impeding the progress of the cancer stem cells market.

Restraint

Risks associated with transplantation and expensive cell therapy

Stem cell transplants involve high-risk procedures, including intense radiation therapy for cancer treatment. This therapy can damage blood-forming cells and leukocytes, necessitating allogeneic or autologous hematopoietic stem cell transplantation. These treatments are costly, with FDA-approved CAR-T stem cell transplantation costing around USD 419,500. Insurance coverage for stem cell therapies is limited, as they are considered experimental. Chemotherapy and transplantation, common cancer treatments, also have their own side effects, such as a weakened immune system. The specific clinical side effects vary based on the type of transplant, overall health, and other individual factors.

Opportunity

Increasing investment and research and development activities

The surge in cancer cases has resulted in an increased need for research-oriented endeavors within the field. The growing demand for treatment and medication, driven by the rising number of cancer types such as leukemia, lymphoma, and osteopetrosis, has led to a higher demand for cancer stem cell therapy as a form of treatment. The extensive research and development activities aimed at advancing cancer treatment and medications, coupled with significant investments from major pharmaceutical companies and government bodies to establish research centers and combat cancer, are collectively fueling the expansion of the cancer stem cells market.

• In January 2023, the merger between First Light Acquisition Group and Calidi Biotherapeutics, Inc. was announced. This collaboration aims to establish a clinical-stage biotechnology company focused on developing oncolytic virotherapy through a stem cell-based cancer treatment delivery platform.

  Cancer Stem Cells Market

  Share, by end user, (USD Billion)

  1.91 Billion%

  Stem Cell-based Cancer Therapy

  Targeted Cancerous Stem Cells

  Other End-Users

  

  5.8 Billion

  Total Market Size

  USD (Billion),

  12.15%

  CAGR

  -

Cancer Stem Cells Market Key Players

• Thermo Fisher Scientific, Inc.
• AbbVie, Inc.
• Merck KGaA
• Bionomics
• Lonza
• Stemline Therapeutics, Inc.
• Miltenyi Biotec
• PromoCell GmbH
• MacroGenics, Inc.
• OncoMed Pharmaceuticals, Inc.
• FUJIFILM Irvine Scientific
• STEMCELL Technologies.
• Sino Biological, Inc.
• Lineage Cell Therapeutics, Inc.

Cancer Stem Cells Market Segment

• By Type

1. Breast
2. Bladder
3. Blood
4. Lung
5. Brain
6. Colorectal
7. Pancreatic
8. Liver

• By Applications

1. Stem Cell-based Cancer Therapy
2. Targeted Cancerous Stem Cells

• By End-use

1. Hospitals
2. Clinics
3. Others

Recent Developments

• In February 2024, Thumbay University Hospital launched the Cancer Center at Thumbay University in Al Jurf, Ajman. The fully equipped center will be active by the end of February 2024. The rising demand for cancer treatment and screening in the Northern Emirates resulted in the launch of these centers. The cancer center will offer affordable cancer care focusing on multidisciplinary treatment.
• In February 2024, the most prevalent area of development in cancer treatment was NexCAR19, India’s first solely developed and launched CAR-T therapy which is given to patients who are suffering from blood cancer and is now available commercially.
• In February 2024, Glenmark Pharma, in collaboration with Ichnos Science, announced the Ichnos Glenmark Innovation (IGI) to increase the drug delivery in cancer treatment.
• In February 2024, a global innovation-driven healthcare organization, “Zydus Lifesciences Ltd.” launched the Relugolix under the name of Rexigo™. It is the first oral therapy for patients having testosterone suppression and the advanced prostate cancer in India.
• In February 2024, Delfi Diagnostics came into a strategic partnership with Immunocore and announced the launch of a new cancer monitoring test that searches blood for broken pieces of tumor DNA.

• In February 2024, the Royal Surrey NHS Foundation Trust in the United Kingdom announced the start of the clinical trial for the early-stage bowled cancer vaccination for patients from Australia and the United Kingdom.

  Cancer Stem Cells Market

  Size, by Product, - (USD Billion)

  The Market will Grow

  At the CAGR of:

  12.15%

  The Forecast Market

  Size for in USD:

  $5.8 Billion

  

Conclusion

The global cancer stem cells market is projected to experience significant growth, expanding from USD 1.91 billion in 2024 to approximately USD 5.8 billion by 2032, with a compound annual growth rate (CAGR) of 12.15%. This growth is driven by the increasing prevalence of cancer worldwide and substantial investments in cancer treatment development. Key trends include the integration of stem cells in healthcare for tissue regeneration and as carriers of anti-cancer drugs, leading to favorable outcomes in tumor treatment. However, high costs and stringent regulations remain significant barriers.

Market dynamics reveal that the rising cases of cancer and increased funding for global cancer research and development programs are primary growth drivers. Despite these advancements, risks associated with transplantation and the high costs of cell therapy pose challenges. The opportunities in the market are bolstered by increasing investments and research activities aimed at developing new treatments and medications for various cancer types.

Key players in the market include Thermo Fisher Scientific, AbbVie, Merck KGaA, and others, actively contributing to advancements in cancer stem cell therapy. Recent developments, such as mergers, new cancer center launches, and innovative cancer treatments, highlight the ongoing progress in this field.

In conclusion, the cancer stem cells market is set to expand significantly due to rising cancer cases, increased investment in research and development, and the successful integration of stem cells in cancer treatment. Despite challenges like high costs and regulatory hurdles, the market's growth trajectory remains strong, supported by continuous innovation and strategic collaborations within the industry.

Cancer Stem Cells Market TO (USD BN)

CAGR OF

12.15%

Cancer Stem Cells Market

5.8 Billion%